Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 831–840 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 831

    Medicine slug
    leflunomide
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    25
    Source count
    25
    Agreement rate
    1
    Recorded readings

    1. 99%

      Numeric value
      99
      Unit
      %
      Source records
      25

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 25 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c288d1d3-3fbe-4c34-a28a-923d515809b3 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d6f5c510-9ec2-4e2d-b134-25c35bd23fee (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af836cd0-da42-772e-e053-2995a90ac103 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:753453c5-8a7a-878e-3ce7-1d1edce718a9 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:320f63f2-fac3-4aee-aff8-85724e00ef52 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a48e6ef2-48ad-4fcf-9e67-dbba83ab0b79 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b9af9870-014f-4c4e-8738-bb04b30b3e85 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:acf3efe4-0d70-4718-9c50-789d69ab215d (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:91712aad-d96c-4ef0-97e7-b31ed18ca6d8 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa5f71b3-6a56-4616-baf7-4b761023b2a9 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b365514-c859-ff93-e053-2a95a90ac698 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6a4107e-b393-45ed-8e5a-70af5bd53826 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c358276a-610e-46da-b81a-95c837af205d (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af4079af-c127-476e-a2b3-53b438dc9da4 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a4f8671-b632-4cc5-8dc9-6b863e62b467 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:006b5bf4-97c0-48dc-8e5e-3c6f64d7bdc1 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:40dd071a-d07f-452f-bf1a-2a23b9d22ca4 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fc044417-cd9a-42f6-8a3d-a14e7c2f81a2 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c66cacd1-93f7-483a-a2fc-aad53d5342b0 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b5c98d0-de59-85f6-e063-6394a90ab67a (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0fb9685-9e54-44e5-b543-1077e1a620c6 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e76d7767-744f-4e52-956d-e59f7a924826 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b5f387e-b52b-ad80-e063-6394a90a56d5 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e85c4eed-794c-409b-aed5-3c857b14b1fb (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5d48fded-b43b-461a-8488-ca1da5c41a03 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.

  2. Projected row 832

    Medicine slug
    leflunomide
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    25
    Source count
    25
    Agreement rate
    1
    Recorded readings

    1. 11 L

      Numeric value
      11
      Unit
      L
      Source records
      25

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 25 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c288d1d3-3fbe-4c34-a28a-923d515809b3 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d6f5c510-9ec2-4e2d-b134-25c35bd23fee (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af836cd0-da42-772e-e053-2995a90ac103 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:753453c5-8a7a-878e-3ce7-1d1edce718a9 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:320f63f2-fac3-4aee-aff8-85724e00ef52 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a48e6ef2-48ad-4fcf-9e67-dbba83ab0b79 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b9af9870-014f-4c4e-8738-bb04b30b3e85 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:acf3efe4-0d70-4718-9c50-789d69ab215d (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:91712aad-d96c-4ef0-97e7-b31ed18ca6d8 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa5f71b3-6a56-4616-baf7-4b761023b2a9 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b365514-c859-ff93-e053-2a95a90ac698 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6a4107e-b393-45ed-8e5a-70af5bd53826 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c358276a-610e-46da-b81a-95c837af205d (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af4079af-c127-476e-a2b3-53b438dc9da4 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a4f8671-b632-4cc5-8dc9-6b863e62b467 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:006b5bf4-97c0-48dc-8e5e-3c6f64d7bdc1 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:40dd071a-d07f-452f-bf1a-2a23b9d22ca4 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fc044417-cd9a-42f6-8a3d-a14e7c2f81a2 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c66cacd1-93f7-483a-a2fc-aad53d5342b0 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b5c98d0-de59-85f6-e063-6394a90ab67a (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0fb9685-9e54-44e5-b543-1077e1a620c6 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e76d7767-744f-4e52-956d-e59f7a924826 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b5f387e-b52b-ad80-e063-6394a90a56d5 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e85c4eed-794c-409b-aed5-3c857b14b1fb (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5d48fded-b43b-461a-8488-ca1da5c41a03 (opens source in a new tab)

        Leflunomide label

        Version not recorded · Effective date not recorded

        The volume of distribution is 11 L after a single intravenous (IV) administration.

  3. Projected row 833

    Medicine slug
    lenalidomide
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    20
    Source count
    20
    Agreement rate
    1
    Recorded readings

    1. 3 hours

      Numeric value
      3
      Unit
      hours
      Source records
      20

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 20 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dffe719b-4f61-47e2-b71c-673322d487f5 (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM or MDS.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b2716cf-24b4-4157-a218-58ede63917bd (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS or MCL.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9959cd7e-12b6-4b59-8205-d5f6e7e7d09b (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM or MDS.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85f5db5d-8f76-46f6-b975-6acda8c4b2c8 (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS or MCL.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9943e098-20b0-dbb3-af12-7816eedd3f70 (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS or MCL.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca8cc2cc-c856-e676-4f60-1e46d7b53d73 (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS, or MCL.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5fa97bf5-28a2-48f1-8955-f56012d296be (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS or MCL.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da7b5dda-79ed-4c4a-88aa-52394fdc7c54 (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 hours to 5 hours in patients with MM or MDS.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c98fb504-76d0-4c25-9c0b-412885828a7a (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM or MDS.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9c414531-a3bf-455a-aca7-9e716f42099a (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS or MCL.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f27092f3-3977-4f4a-b214-45309e136e46 (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS or MCL.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:682e8a86-9f49-45db-a2ea-403ee1dc62d2 (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS or MCL.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2166bbdf-eb12-4564-b9e4-b63ca21312bc (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 hours to 5 hours in patients with MM, MDS or MCL.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51bfdd53-8fd9-4f86-bebe-75de29e6379d (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM or MDS.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba2a07fd-ca60-40bc-b79b-9caf81900fa3 (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS or MCL.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:84d9dec7-9250-4dbd-9a0d-23e75f111892 (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with Metabolism Lenalidomide undergoes limited metabolism.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:96df285d-dd13-4083-b2c6-e5c799e7587b (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS or MCL.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed7a3099-ce31-4865-b212-358d9ff6261b (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS or MCL.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:adee5af1-c9ab-c0c7-e400-dea7d2a0d4be (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM or MDS.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76f6c1e7-985b-43d9-892c-849df50ae80e (opens source in a new tab)

        Lenalidomide label

        Version not recorded · Effective date not recorded

        Elimination The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS or MCL.

  4. Projected row 834

    Medicine slug
    letrozole
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    24
    Source count
    24
    Agreement rate
    1
    Recorded readings

    1. 2 days

      Numeric value
      Not parsed
      Unit
      Not recorded
      Source records
      24

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 24 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b408ba8-05f7-1cf1-e063-6394a90a42bc (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26dcb6ee-74d8-4804-b151-79a41484979b (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35c73219-c39e-4e10-b944-76009b061e79 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2-6 weeks.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff7325d2-3383-4ff9-a187-9350e3538640 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d1f18f0-2c77-407c-b702-2d1b07f92510 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:82b77d74-085f-45ac-a7dd-1f5c038bf406 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2-6 weeks.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6cfd29d7-f519-7b8c-4814-07b39f367f0d (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2-6 weeks.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ebda73d-82a3-4b17-8a81-a1f258003d32 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c391fe11-fd47-4a35-af6d-c823ab7b8838 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3baa3912-3e64-473b-8ec6-8557aa7907c2 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole's terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2-6 weeks.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3cc750a5-cc88-4b42-b4ab-a87e760f291d (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole's terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2-6 weeks.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a707ec4b-8d26-55c2-e053-2a95a90a2e07 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fd92634-c9c5-457e-808c-a4614e8db7db (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32d7dd83-a3ef-41fe-e063-6394a90ae62a (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b00e08c-9a1c-09e0-e053-2a91aa0a7638 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1524730f-e37d-478c-1956-b113b3ca42a8 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93f317f1-96d1-498e-e053-2995a90ac60d (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole's terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2-6 weeks.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63e54b62-a30d-4a56-9215-75e7a0b0bf02 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole's terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2-6 weeks.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:065cc89f-3a3f-4d78-b9f6-1c32a77ceb1c (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e1390a0d-0280-49a5-a2d4-d2e13e9952ca (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c10bf97f-f9cf-468a-8a1f-7637f41022e4 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa2d40a5-3504-44ef-8f5c-aa4c06308074 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe0e4d4b-436d-a36d-e053-6294a90a973d (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2 to 6 weeks.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb1da0ac-8db1-4482-824d-430511d1b7a0 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2-6 weeks.

  5. Projected row 835

    Medicine slug
    letrozole
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    24
    Source count
    24
    Agreement rate
    1
    Recorded readings

    1. 1.9 L/kg

      Numeric value
      1.9
      Unit
      L/kg
      Source records
      24

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 24 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b408ba8-05f7-1cf1-e063-6394a90a42bc (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26dcb6ee-74d8-4804-b151-79a41484979b (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35c73219-c39e-4e10-b944-76009b061e79 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff7325d2-3383-4ff9-a187-9350e3538640 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d1f18f0-2c77-407c-b702-2d1b07f92510 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:82b77d74-085f-45ac-a7dd-1f5c038bf406 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6cfd29d7-f519-7b8c-4814-07b39f367f0d (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ebda73d-82a3-4b17-8a81-a1f258003d32 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c391fe11-fd47-4a35-af6d-c823ab7b8838 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3baa3912-3e64-473b-8ec6-8557aa7907c2 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3cc750a5-cc88-4b42-b4ab-a87e760f291d (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a707ec4b-8d26-55c2-e053-2a95a90a2e07 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fd92634-c9c5-457e-808c-a4614e8db7db (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32d7dd83-a3ef-41fe-e063-6394a90ae62a (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b00e08c-9a1c-09e0-e053-2a91aa0a7638 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1524730f-e37d-478c-1956-b113b3ca42a8 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93f317f1-96d1-498e-e053-2995a90ac60d (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63e54b62-a30d-4a56-9215-75e7a0b0bf02 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:065cc89f-3a3f-4d78-b9f6-1c32a77ceb1c (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e1390a0d-0280-49a5-a2d4-d2e13e9952ca (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c10bf97f-f9cf-468a-8a1f-7637f41022e4 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa2d40a5-3504-44ef-8f5c-aa4c06308074 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe0e4d4b-436d-a36d-e053-6294a90a973d (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb1da0ac-8db1-4482-824d-430511d1b7a0 (opens source in a new tab)

        Letrozole label

        Version not recorded · Effective date not recorded

        Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).

  6. Projected row 836

    Medicine slug
    leucovorin
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    24
    Source count
    23
    Agreement rate
    1
    Recorded readings

    1. 97%

      Numeric value
      97
      Unit
      %
      Source records
      23

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 23 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ab691d4e-e0d1-4ba1-9c7a-1cdcfcc3c17c (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79d023ab-7d77-48c1-8f47-ea322fd58c2b (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2627a485-05b5-4dab-ac20-dc840e5c469d (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg and 37% for 100 mg.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8102043-79f2-421a-b849-94bac19007a6 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        Absorption Following oral administration of leucovorin in adults, the apparent bioavailability of levoleucovorin is 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg, and dextroleucovorin is approximately 19% for 25 mg, 20% for 50 mg, and 7% for 100 mg.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5d4f0fd-7520-43a9-9acc-f7e117e1f6ee (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e9b47126-8b52-43ff-85c4-33d32b3d8326 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:968b192b-72f3-41b0-a1f5-bab8a96d3419 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8bdd60c-9a1c-4ef4-ba6b-b911849128f1 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d0e5356-ff39-4a8e-944c-e808a21ef4b2 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0cbcbf6-6fd2-4cf3-877a-bb0fe3df4e59 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cc52077f-5663-4f79-a273-0aecf655e038 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94669fc8-3c1c-4228-be27-09a1cd468c36 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        Absorption Following oral administration of leucovorin in adults, the apparent bioavailability of levoleucovorin is 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg, and dextroleucovorin is approximately 19% for 25 mg, 20% for 50 mg, and 7% for 100 mg.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:33663425-4731-4977-9127-9e59b6b91497 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        Absorption Following oral administration of leucovorin in adults, the apparent bioavailability of levoleucovorin is 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg, and dextroleucovorin is approximately 19% for 25 mg, 20% for 50 mg, and 7% for 100 mg.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7004cbd-9827-466e-9683-adce4f13c6a6 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg and 37% for 100 mg.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f198ab39-9394-4280-be44-93a88264a450 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9df20901-6980-4d4e-89ec-40f3c1f91852 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b72d1fd-f389-45d9-b43b-510b45c92263 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f579879c-7d53-4663-8ad8-84b8b645cda5 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7409cdee-9093-47af-a4c4-2c55ce1b6361 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        Absorption Following oral administration of leucovorin in adults, the apparent bioavailability of levoleucovorin is 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg, and dextroleucovorin is approximately 19% for 25 mg, 20% for 50 mg, and 7% for 100 mg.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1cb701ca-2478-4268-9d69-80293965d59d (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:46d12bd0-ec7d-4e2c-aeed-b8aa88e6dc5c (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg and 37% for 100 mg.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3b957dc-a542-4f69-b8a0-7df401ee706f (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:273407f5-0be2-435a-b7a8-f21be8ffbb3c (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg and 37% for 100 mg.

  7. Projected row 837

    Medicine slug
    leucovorin
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    24
    Source count
    20
    Agreement rate
    0.75
    Recorded readings

    1. 6.2 hours

      Numeric value
      6.2
      Unit
      hours
      Source records
      15

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 15 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ab691d4e-e0d1-4ba1-9c7a-1cdcfcc3c17c (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79d023ab-7d77-48c1-8f47-ea322fd58c2b (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5d4f0fd-7520-43a9-9acc-f7e117e1f6ee (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e9b47126-8b52-43ff-85c4-33d32b3d8326 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:968b192b-72f3-41b0-a1f5-bab8a96d3419 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8bdd60c-9a1c-4ef4-ba6b-b911849128f1 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d0e5356-ff39-4a8e-944c-e808a21ef4b2 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0cbcbf6-6fd2-4cf3-877a-bb0fe3df4e59 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cc52077f-5663-4f79-a273-0aecf655e038 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f198ab39-9394-4280-be44-93a88264a450 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9df20901-6980-4d4e-89ec-40f3c1f91852 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b72d1fd-f389-45d9-b43b-510b45c92263 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f579879c-7d53-4663-8ad8-84b8b645cda5 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1cb701ca-2478-4268-9d69-80293965d59d (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3b957dc-a542-4f69-b8a0-7df401ee706f (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        The terminal half-life for total reduced folates was 6.2 hours.

    2. 0.5-1.3 hours

      Numeric value
      0.5
      Unit
      hours
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8102043-79f2-421a-b849-94bac19007a6 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        Elimination After intravenous administration of leucovorin in adults, the reported mean plasma elimination half-life in the literature was 0.5-1.3 hours for levoleucovorin and 3-7 hours for 5-MTHF.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94669fc8-3c1c-4228-be27-09a1cd468c36 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        Elimination After intravenous administration of leucovorin in adults, the reported mean plasma elimination half-life in the literature was 0.5-1.3 hours for levoleucovorin and 3-7 hours for 5-MTHF.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:33663425-4731-4977-9127-9e59b6b91497 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        Elimination After intravenous administration of leucovorin in adults, the reported mean plasma elimination half-life in the literature was 0.5-1.3 hours for levoleucovorin and 3-7 hours for 5-MTHF.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7409cdee-9093-47af-a4c4-2c55ce1b6361 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        Elimination After intravenous administration of leucovorin in adults, the reported mean plasma elimination half-life in the literature was 0.5-1.3 hours for levoleucovorin and 3-7 hours for 5-MTHF.

    3. 9.5 hours

      Numeric value
      9.5
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d122b875-435e-4e00-b945-7a0546df95c2 (opens source in a new tab)

        Leucovorin label

        Version not recorded · Effective date not recorded

        Elimination Leucovorin estimated terminal half-life is approximately 9.5 hours (CV 17%).

  8. Projected row 838

    Medicine slug
    leuprolide
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    24
    Source count
    11
    Agreement rate
    1
    Recorded readings

    1. 3 hours

      Numeric value
      3
      Unit
      hours
      Source records
      11

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 11 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7a8761a-d953-413a-e053-2a95a90a60ee (opens source in a new tab)

        Leuprolide label

        Version not recorded · Effective date not recorded

        Elimination The mean systemic clearance was 7.6 L/h and terminal elimination half-life of approximately 3 hours following an intravenous bolus of leuprolide in healthy male volunteers.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:008776cc-83f1-4f8c-819b-6471425da15f (opens source in a new tab)

        Leuprolide label

        Version not recorded · Effective date not recorded

        In healthy male volunteers, a 1-mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 8.34 L/h, with a terminal elimination half-life of approximately 3 hours based on a two compartment model.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d6bd26bd-b8d8-4c5a-bc5c-7b8a1efaa584 (opens source in a new tab)

        Leuprolide label

        Version not recorded · Effective date not recorded

        Metabolism In healthy male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 7.6 L/h, with a terminal elimination half-life of approximately 3 hours based on a two compartment model.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cd46628f-055f-4da9-8c38-fa69af34eb4d (opens source in a new tab)

        Leuprolide label

        Version not recorded · Effective date not recorded

        Metabolism In healthy male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 7.6 L/h, with a terminal elimination half-life of approximately 3 hours based on a two compartment model.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:290b0716-2fd5-43a1-8d3c-4857c1b2eefa (opens source in a new tab)

        Leuprolide label

        Version not recorded · Effective date not recorded

        Metabolism In healthy male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 7.6 L/h, with a terminal elimination half-life of approximately 3 hours based on a two compartment model.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c311700-edf4-4f2a-a468-9875489a6cc7 (opens source in a new tab)

        Leuprolide label

        Version not recorded · Effective date not recorded

        In healthy male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 8.34 L/h, with a terminal elimination half-life of approximately 3 hours based on a two-compartment model.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b78d1919-9dee-44fa-90f9-e0a26d32481d (opens source in a new tab)

        Leuprolide label

        Version not recorded · Effective date not recorded

        In healthy male volunteers, a 1-mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 8.34 L/h, with a terminal elimination half-life of approximately 3 hours based on a two compartment model.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19be0b7f-e68a-4547-9e49-b51b12821907 (opens source in a new tab)

        Leuprolide label

        Version not recorded · Effective date not recorded

        Metabolism In healthy male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 7.6 L/h, with a terminal elimination half-life of approximately 3 hours based on a two compartment model.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4838c674-044e-46b2-81e7-c691b99d8fa5 (opens source in a new tab)

        Leuprolide label

        Version not recorded · Effective date not recorded

        Metabolism In healthy male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 7.6 L/h, with a terminal elimination half-life of approximately 3 hours based on a two compartment model.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0cf31b40-816b-d055-e063-6294a90af5d0 (opens source in a new tab)

        Leuprolide label

        Version not recorded · Effective date not recorded

        Metabolism In healthy male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 7.6 L/h, with a terminal elimination half-life of approximately 3 hours based on a two compartment model.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b7b679a9-6823-4ef8-8d31-3ab5058ffcfc (opens source in a new tab)

        Leuprolide label

        Version not recorded · Effective date not recorded

        In healthy male volunteers, a 1-mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 8.34 L/h, with a terminal elimination half-life of approximately 3 hours based on a two compartment model.

  9. Projected row 839

    Medicine slug
    leuprolide
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    24
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 5 hours

      Numeric value
      5
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:008776cc-83f1-4f8c-819b-6471425da15f (opens source in a new tab)

        Leuprolide label

        Version not recorded · Effective date not recorded

        VABRINTY 22.5 mg Following a single injection of VABRINTY 22.5 mg for 3-month administration in patients, the mean peak plasma concentration was 127 ng/mL (C max ) at 5 hours; at the end of the 12 week dosing interval the mean concentration declined to 0.34 ng/mL.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b7b679a9-6823-4ef8-8d31-3ab5058ffcfc (opens source in a new tab)

        Leuprolide label

        Version not recorded · Effective date not recorded

        ELIGARD 22.5 mg Following a single injection of ELIGARD 22.5 mg for 3-month administration in patients, the mean peak plasma concentration was 127 ng/mL (C max ) at 5 hours; at the end of the 12 week dosing interval the mean concentration declined to 0.34 ng/mL.

  10. Projected row 840

    Medicine slug
    levetiracetam
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    165
    Source count
    114
    Agreement rate
    1
    Recorded readings

    1. 100%

      Numeric value
      100
      Unit
      %
      Source records
      114

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 114 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a688786-879b-4e27-a46a-5c86bbfa1292 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c82313cb-744f-45ef-b74c-1bdd055b2193 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30a4626d-74f3-6385-e063-6394a90a2950 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d67cb3c-1173-4dce-a79b-a3c36934ab2e (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d307850-0ed5-4f32-ac62-0e1e2fe27a7a (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e662bf5b-c81c-4bcd-ba2e-552df95ca6f9 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3b62114-a590-f4db-e053-2995a90a9d30 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets or oral solution are bioequivalent in rate and extent of absorption.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1e988f7-8bbe-4ef4-8b0a-b2a8af8a482b (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:591dd9f1-3681-4b2f-b096-7536826e3648 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dfc218c5-672a-420a-b59e-2e0b054e99ad (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51b66893-f7d6-8f9d-e063-6294a90a8e9b (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fc4c72e2-9cba-88d9-e053-6394a90a0426 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43df4156-0958-e496-e063-6294a90a5329 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0348fec4-d919-4307-ac90-35360819bc00 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6913c611-4994-4501-8ed9-45161f90373e (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6bdbc193-d86b-4bd5-8e88-4ea964d2cdde (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f3c04d9-cccb-06a3-a0f3-f7c9228ee743 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e31c6830-4647-4481-b4f1-494a52c48b1b (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c4b27429-50a3-467c-a5ff-7e49a01a1088 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a3c57d82-511c-4c7d-84ff-f791f931f576 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53843871-23e3-974e-e063-6394a90a8042 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:551626eb-3282-e439-e063-6294a90a8314 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1c4450a1-6c05-4b45-a733-c19b4e861970 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c4a3018a-3cd8-4e07-a840-099ceae01c91 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d818ef84-9b3e-434b-92d9-910cfa8af7da (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed8e88d0-993e-4683-bdcf-31578130d3df (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c2177034-e164-453c-be02-1cf91ce27a07 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08e1bfea-7f3f-42d9-823d-f75080e664ff (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a987d59-560f-4650-96ec-31aec81953b5 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc12f0b0-e05c-48e4-ad08-0ff14a818a64 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b9597cd5-5745-494a-bd72-93071ed221da (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3884cb76-822b-400d-9b24-49c286c9b6f7 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e3171c9-70e2-4725-8aca-c7f83773940d (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7696961e-dfff-422a-b72f-e31ceeac10af (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:423d2185-0931-4414-8864-7594000809ee (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:01aef7f7-6092-4e39-8451-dc02d8db9254 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9dca1330-52ca-47a4-a134-ec55c9d5786d (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2471ee03-d747-4113-86d0-1aa93c8f3eba (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f65ec19d-b90e-452e-b761-c68b1cf2c892 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b74b8bc-d95c-4471-8f74-c3117243bf89 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8c16bc7b-672c-420a-a457-350060533375 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e77162ff-0ff9-45ca-95fc-da6ea24ce5a2 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e72a7410-13fd-40e4-befb-052d0455e038 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d75b15e-881c-a00f-e063-6394a90a4138 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:513f422f-1637-5f41-e063-6294a90ab548 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df661166-325d-4071-9bc1-f7bf992996d2 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f924d55d-d7ec-4448-b54e-3a7eaf5a1cab (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a05bbfa4-c34f-4134-8207-db79e4c70445 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be651c31-383f-11e4-916c-0800200c9a66 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5037a86a-21f2-d793-e063-6394a90a2cb5 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30f43d3b-c944-4f25-b5d3-009294944962 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dfb7c640-623e-43d1-8ee8-479dccd53d0a (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8a8472dc-b97e-445d-bf51-b6e618cae1b6 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fc8bf57e-8aa2-4d3c-856d-b19de65e3ba0 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:792db8dc-177b-4864-8600-12823819082d (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5eb7bea5-c95f-4a38-a5bb-c20d1549c797 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e31e766-6504-4f20-8831-1953363cace0 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:671a1ae1-f672-48da-8a69-94c147472003 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58ed7049-44c6-4f97-9174-c0e1504586a6 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3daf220-9741-41c4-b89d-e06cee36dac6 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd713e60-478c-43cd-b680-ff594a0b3864 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4781ec4-43ad-4052-9a6a-b24fda119b32 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a91defd2-486b-4995-ba4c-640525ab575d (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae405796-1eca-4890-bcb2-e1b07654a24d (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc8b413f-2f07-4e6a-bb8e-a1f2119ae1cf (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5c4877cc-52bc-4f98-a995-0aa9439da742 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0bc8468f-832c-4e71-95a2-db464d4d54bc (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:db423b93-d7c2-4cf2-829b-24b657f27f93 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45a07f44-078d-0513-e063-6394a90a1629 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ca9df05-a506-4ec8-a4fe-320f1219ab21 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57f09129-7151-4a75-9d73-9dd32f74ba43 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3756f052-919c-4817-a56e-1091fd514d9d (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba18ead0-69d7-453a-badc-cd6ad376d18e (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:90e01877-abcb-4697-a7ed-9afe5ee77050 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1c26c0ad-9d37-45c5-9091-849509f4fc01 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bb6e1c75-66eb-4d18-af70-9b51fb67c4d6 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56fed03f-38c3-4273-8fd7-522bc508bf36 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:567f09e6-ccd5-4688-a22b-0bc66a5fe31e (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:34af3602-0188-4d2e-904b-2e40000bb45c (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:adbcb0f7-0421-47e2-854e-e1cfefb6386f (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b738377c-035e-4b2e-9909-0a8fe07aa0fb (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d596153-c49b-273f-e063-6294a90ac663 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45a03a43-04db-9138-e063-6394a90a12fa (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28c0e61e-1af9-410a-9fa9-b71bf99a776b (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d71212b-ac97-4a61-8192-8e8303540019 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c12d8af3-39a8-4690-8d47-43dec70b7579 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:031a32e1-675a-4efe-a66b-40beb4fe5101 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ec4c05d-7fba-4c02-a3bf-4343a8a421d5 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:483a42b9-c8f3-4f8b-98be-fcac5ab23c7c (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3be7c30b-f35d-4dde-8bf8-24f67bd70865 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:deca634a-651e-4c70-9fc3-b0087b537b0a (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23073db5-3fc4-4051-a22d-e49a63e42647 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5517b148-1eff-6421-e063-6394a90a9498 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:49117cee-a96c-4593-91a7-8a133e3f0939 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd175fa3-1d7a-4542-affd-988ac5bba1db (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61eb57a9-5df2-4426-9f0c-a75e2f356b11 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bf412e94-ca36-4da9-83d7-fb0f1323cf21 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:24f815ef-58e6-42b9-8137-adcd6c382aa6 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52fa0eec-3dd9-59ca-e063-6394a90a9791 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:74ccc9f1-b957-4b1b-9464-1b5e3318c916 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:266d4ead-fda2-f030-e063-6394a90a68e2 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1b28234-1f7c-40bf-80a7-6cc98b3839fe (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:419b3dba-ae21-4268-ac8b-342aaa609554 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02e237ff-a3e0-40fe-a3d0-9d8802855c71 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e1ebd960-79a4-4632-b727-4e9811824113 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee03507b-cb35-4fe9-ae7b-85ea89f876f0 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5cb4a1db-f32d-44af-8985-0a94ca506468 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7c96494-6cb2-4d00-8c5a-5bec4e0c70c0 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7932a2c-a3b7-46df-a306-1f17716160a0 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6ab24168-058d-496e-9023-da8ee6353eb3 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63b36274-89f0-42d8-9f09-f9e78e179af4 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94d042f7-93b9-43bd-9ace-cfc61903b4d7 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c4b2da6a-ed50-4a54-90bd-32f76b178736 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e1b14939-7262-40dc-a334-2b3b72c88d47 (opens source in a new tab)

        Levetiracetam label

        Version not recorded · Effective date not recorded

        The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=830

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy